A series of biopharma and patient advocacy stakeholders helped to derail the modified House version of the right-to-try legislation, even though they played a role in adding what they felt were necessary changes to the bill. But their continued opposition may have cost them from any of their desired fixes, former US Food and Drug Administration commissioner Scott Gottlieb suggested.
In an exclusive interview with the Pink Sheet and sister publication Medtech Insight, Gottlieb, now a resident fellow at the American Enterprise Institute, opined that stakeholder opposition to
